Sleep-disordered breathing (SDB) is a risk factor for cardiovascular disease including acute coronary syndrome and acute myocardial infarction, and treating SDB prevents their development and recurrence and improves a patient's prognosis. Therefore, SDB is considered a therapeutic target for cardiovascular disease. In 2010, the Japanese Circulation Society published guidelines for the diagnosis and treatment of SDB in patients with cardiovascular disease. However, therapeutic intervention for patients with SDB was recently reported not to suppress the development or deterioration of cardiovascular disease in three middle-to large-sized randomized clinical trials: the SERVE-HF trial, which examined the effects of adaptive servo-ventilation (ASV) on patients with chronic heart failure (CHF) and central sleep apnea; the CAT-HF trial, which examined the effects of ASV therapy on patients with CHF after acute deterioration; and the SAVE study, which examined the secondary preventive effect of continuous positive airway pressure (CPAP) on patients with ischemic heart disease who had mild to moderate obstructive sleep apnea. These studies caused hesitation among clinicians to proactively treat SDB by ASV or CPAP therapy. The present review is focused on hypertension, pulmonary hypertension, ischemic heart disease, and CHF to newly summarize the studies available to date from the viewpoints of epidemiology, pathogenesis, and treatment. I expect this review be informative and useful for physicians who treat patients with SDB by CPAP or ASV therapy in the clinical setting. (J Nippon Med Sch 2018; 85: 70 77) 
Introduction
Sleep-disordered breathing (SDB) is a risk factor for cardiovascular disease 1 7 , and several clinical studies have
shown that the treatment of SDB prevents its development and recurrence and improves the patient's prognosis 7 9 . Therefore, the understanding that SDB is a therapeutic target for cardiovascular disease has grown rapidly since the year 2000. In 2010, the Japanese Circulation Society published guidelines for the diagnosis and treatment of SDB in patients with cardiovascular disease (JCS 2010) 10 . However, three middle-to large-sized randomized clinical trials 11 13 have shown that therapeutic intervention for patients with SDB did not suppress the development or deterioration of cardiovascular disease. The first of the studies was the SERVE-HF trial, which examined the effects of adaptive servo-ventilation (ASV) on patients with chronic heart failure (CHF) that was complicated by central sleep apnea (CSA); the study attracted much attention because of having suggested an increased cardiovascular mortality, though ASV therapy improved SDB compared with no provision of treatment 11 . The second of the studies was the CAT-HF trial, which examined the effects of ASV therapy on patients with CHF after acute deterioration; the study was discontinued due to the reported outcomes from the SERVE-HF trial, and its results were analyzed under the situation that the target number of patients was not reached 12 . Consequently, ASV therapy showed no significant effect on patients with CHF. The third of the studies was the SAVE study, which examined the secondary preventive effect of continuous positive airway pressure (CPAP) on patients with ischemic heart disease who had mild to moderate ob- 15, 16 . Moreover, the prevalence of SDB is very high (80%) in patients with drug-resistant hypertension 17 .
Pathogenesis
Upper airway obstruction, which causes OSA in many patients with hypertension, is determined by morphological factors (e.g., small cross-section of the airways) and functional factors that are balanced between the tension of the upper airway dilators and the negative pressure of the airway lumen 10 . OSA causes the hyperactivity of the sympathetic nervous system and increases the activity of the renin-angiotensin-aldosterone (RAA) system through the frequent provocation of arousal responses and the intermittent development of hypoxemia and hypercapnia 18 21 ; thus, OSA is known to be involved in the induction and deterioration of hypertension ( Fig. 1 ). An association between sleep apnea syndrome assessed with apnea-hypopnea index (AHI) and the development of hypertension has been found 3 . In addition, OSA is associated with the development of nocturnal hypertension and nondipper hypertension 21 and is known to precede nondipper hypertension 22 . Hence, the Guidelines for the Management of Hypertension in Japan 23 recognize the following: 1) OSA does not originate from hypertension but is a risk factor for the induction and deterioration of hypertension; and 2) it is essential to adequately diagnose and treat OSA in patients with hypertension. In particular, OSA is the most common factor for secondary hy-pertension in patients with resistant hypertension 24 .
Therefore, physicians should actively suspect the presence of OSA and conduct a sleep test.
Treatment
The obesity-induced deposition of fat in upper airway soft tissue is considered to be the most important risk factor for OSA. Therefore, weight reduction should be at- hour of CPAP therapy) 26 . CPAP therapy was associated with a lower risk of hypertension 27, 28 . The minimum threshold duration of CPAP therapy per night to obtain the hypotensive effect is considered to be 4 hours 25, 29, 30 , with the optimal duration being 5 to 6 hours 
Pathogenesis
OSA is one of the etiologies of pulmonary hypertension. Similar to hypertension, therefore, not only hypoxia and frequent arousal but also decreased intraperitoneal pressure is included in the putative pathophysiologic mechanisms ( Fig. 1) 10,31 33 .
Treatment
The treatment of first choice is CPAP therapy when OSA causes secondary pulmonary hypertension. The treatment of OSA by CPAP therapy is known to lower pulmonary arterial pressure at the time of arousal during the daytime 34 36 . However, CPAP therapy is not indicated for events other than secondary pulmonary hypertension caused by hypoxia. Due to the possibility that positive airway pressure increases pulmonary blood vessel resistance, CPAP therapy cannot be recommended for patients with Group I pulmonary artery hypertension or Group IV chronic thromboembolic pulmonary hypertension that are defined in the Guidelines for the Treatment of Pulmonary Hypertension in Japan (appropriate pharmacotherapy and oxygenation therapy are selected in these patients). Since CPAP therapy cannot be sweepingly considered as a recommended choice for the treatment of pulmonary hypertension, it is therefore mandatory to precisely specify the cause(s) of pulmonary hypertension. 
Ischemic Heart Disease Epidemiology
OSA frequently coexists in patients with coronary artery disease or acute coronary syndromes 37, 38 . The risk of developing ischemic heart disease is 1.2 to 6.9 times greater in patients with OSA than in healthy individuals 6 .
Fatal and nonfatal cardiovascular events were 2.87 and 3.17 times more frequent, respectively, in patients with severe OSA who had an AHI of 30 events/hour than in healthy individuals 7 .
Pathogenesis
OSA is a risk factor for ischemic heart disease. SDBinduced intermittent hypoxia is known to be associated with glucose intolerance independent of age, sex, body mass index, and abdominal circumference 38 . Similar to ischemia-reperfusion injury, moreover, intermittent hypoxia is considered to increase the risk of developing ischemic heart disease by decreasing the endothelial function of the coronary arteries through inflammation and free radicals (Fig. 2) 
39
.
Treatment
CPAP therapy is the treatment of choice for patients with severe OSA, as for patients with other cardiovascular disease. The incidence of cardiovascular events decreased to the level found in healthy individuals when CPAP therapy was conducted in patients with OSA who had an AHI >30 events/hour 7 , which led to the understanding that the treatment of patients with severe OSA is effective for the primary prevention of cardiovascular disease 10 . As described in the first paragraph of this article, however, the SAVE study showed that CPAP therapy does not have any secondary preventive effect on cardiovascular disease and appears to indicate that CPAP therapy for the secondary prevention of cardiovascular disease is meaningless. However, attention should be paid to the facts that the SAVE study 13 excluded patients with severe SDB who had an AHI >30 events/hour and patients whose SaO2 was lowered by SDB, in addition to: 1) concern about the maintenance of treatment level among the study sites and 2) the issue that the average duration of CPAP therapy was less than 4 hours. The SAVE study excluded patients who should undergo CPAP therapy and examined patients with milder OSA. Furthermore, the patients in the RICCADSA randomized controlled trial in coronary artery disease who had no daytime sleepiness showed a cardiovascular risk reduction not in the study population but in a subgroup of patients who underwent ! 4-hour CPAP therapy 40 . Therefore, I consider that CPAP therapy requires a minimum of 4 hours to exert a risk-reducing effect in patients with hypertension or cardiovascular disease. In light of my consideration, the SAVE study does not negate the conventional therapeutic strategy for patients with SDB. At my institution, we routinely conduct pulse oximetry as the first step before hospitalization to screen patients with ischemic heart disease for the presence or absence of intermittent hypoxia dur- of patients who had heart failure with a reduced ejection fraction (HFrEF) 4,42 45 . SDB was found in 55% of a small number of patients who had heart failure with a preserved ejection fraction (HFpEF) 45 .
Pathogenesis
OSA is considered to be one of the etiologies of heart failure 46 . In patients with heart failure, furthermore, socalled "fluid shift," by which body fluids that are retained due to heart failure move to the craniocervical region, is provoked or aggravated by OSA 47 . On the other hand, CSR-CSA occurs as a consequence of heart failure and when both of the following phenomena associated with heart failure progression enhanced chemosensitivity and delayed circulation (i.e., low cardiac output) appear (Fig. 3 ) 48 . Overnight fluid shift to the craniocervical region may also contribute to the pathogenesis of CSA 50 .
Similar to OSA, furthermore, CSR-CSA is also considered as a prognosticator because of repeatedly causing hypoxia and arousal 45, 49 . Meanwhile, however, the SERVE-HF trial indicated that CSR-CSA might increase cardiac output in patients with chronic heart failure. Therefore, CSR-CSA is now under review as to its pathophysiologic role "friend" or "foe" in this patient population 51 .
Treatment
In patients with OSA, CPAP therapy improves not only SDB, but also sympathetic nerve activity 52 CPAP therapy and ASV therapy reduce the transmural pressure of the left ventricle and venous return through positive airway pressure 58, 59 . However, low cardiac output frequently occurs in patients with CHF and CSR-CSA 44 .
CPAP therapy and ASV therapy reduce venous return through positive airway pressure in patients with preserved preload reserve, but they also reduce preload pressure and lower cardiac output. Excessive positive pressures were applied to treat some patients with SDB in both the SERVE-HF trial and the CAT-HF trial, which probably masked the patient prognosis-and cardiac function-improving effects of ASV therapy. Therefore, cardiologists should fully examine whether positive ventilation therapy adversely affects the hemodynamics of patients with CHF when conducting CPAP or ASV therapy and should then initiate and manage the therapy appropriately.
In Japan, the Japanese Circulation Society and the Japanese Heart Failure Society announced a joint statement for the proper use of ASV in patients with heart failure 60 . Readers are invited to read the statement for ref-
erence.
